Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1979 1
1980 1
1983 2
1984 1
1985 1
1986 2
1987 1
1988 1
1989 1
1990 2
1991 3
1992 1
1993 4
1994 3
1995 1
1996 7
1997 10
1998 3
1999 7
2000 5
2001 7
2002 6
2003 5
2004 6
2005 9
2006 14
2007 12
2008 14
2009 14
2010 15
2011 11
2012 16
2013 22
2014 30
2015 30
2016 41
2017 38
2018 35
2019 30
2020 36
2021 30
Text availability
Article attribute
Article type
Publication date

Search Results

417 results
Results by year
Filters applied: . Clear all The following terms were ignored: %, %, %, % The following terms were not found in PubMed: 22Tsong, 5BAuthor
Page 1
Exercise for preventing falls in older people living in the community.
Sherrington C, Fairhall NJ, Wallbank GK, Tiedemann A, Michaleff ZA, Howard K, Clemson L, Hopewell S, Lamb SE. Sherrington C, et al. Cochrane Database Syst Rev. 2019 Jan 31;1(1):CD012424. doi: 10.1002/14651858.CD012424.pub2. Cochrane Database Syst Rev. 2019. PMID: 30703272 Free PMC article.
SELECTION CRITERIA: We included randomised controlled trials (RCTs) evaluating the effects of any form of exercise as a single intervention on falls in people aged 60+ years living in the community. ...Fourteen trials reported no adverse events. Aside from two serio …
SELECTION CRITERIA: We included randomised controlled trials (RCTs) evaluating the effects of any form of exercise as a single interv …
Biologics for chronic rhinosinusitis.
Chong LY, Piromchai P, Sharp S, Snidvongs K, Philpott C, Hopkins C, Burton MJ. Chong LY, et al. Cochrane Database Syst Rev. 2020 Feb 27;2(2):CD013513. doi: 10.1002/14651858.CD013513.pub2. Cochrane Database Syst Rev. 2020. PMID: 32102112 Free PMC article. Updated.
We are very uncertain about the effect of omalizumab on disease-specific HRQL, severe adverse events, extent of disease (CT scan scores), generic HRQL and adverse effects. ...It is uncertain if there is a difference in symptom severity and the risk of serious …
We are very uncertain about the effect of omalizumab on disease-specific HRQL, severe adverse events, extent of disease (CT scan scor …
Aerobic and strength training exercise programme for cognitive impairment in people with mild to moderate dementia: the DAPA RCT.
Lamb SE, Mistry D, Alleyne S, Atherton N, Brown D, Copsey B, Dosanjh S, Finnegan S, Fordham B, Griffiths F, Hennings S, Khan I, Khan K, Lall R, Lyle S, Nichols V, Petrou S, Zeh P, Sheehan B. Lamb SE, et al. Health Technol Assess. 2018 May;22(28):1-202. doi: 10.3310/hta22280. Health Technol Assess. 2018. PMID: 29848412 Free PMC article. Clinical Trial.
Carer outcomes were HRQoL (Quality of Life in Alzheimer's Disease) (as measured using the EQ-5D-3L) and carer burden (as measured using the Zarit Burden Interview). ...Four serious adverse events were reported. The exercise intervention was dominated in health econo …
Carer outcomes were HRQoL (Quality of Life in Alzheimer's Disease) (as measured using the EQ-5D-3L) and carer burden (as measured usi …
Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib.
Hochberg MC, Martel-Pelletier J, Monfort J, Möller I, Castillo JR, Arden N, Berenbaum F, Blanco FJ, Conaghan PG, Doménech G, Henrotin Y, Pap T, Richette P, Sawitzke A, du Souich P, Pelletier JP; MOVES Investigation Group. Hochberg MC, et al. Ann Rheum Dis. 2016 Jan;75(1):37-44. doi: 10.1136/annrheumdis-2014-206792. Epub 2015 Jan 14. Ann Rheum Dis. 2016. PMID: 25589511 Free PMC article. Clinical Trial.
Secondary outcomes included WOMAC function and stiffness, visual analogue scale for pain, presence of joint swelling/effusion, rescue medication consumption, Outcome Measures in Rheumatology Clinical Trials and Osteoarthritis Research Society International (OMERACT-OARSI) criteri …
Secondary outcomes included WOMAC function and stiffness, visual analogue scale for pain, presence of joint swelling/effusion, rescue medica …
Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19.
Cauchois R, Koubi M, Delarbre D, Manet C, Carvelli J, Blasco VB, Jean R, Fouche L, Bornet C, Pauly V, Mazodier K, Pestre V, Jarrot PA, Dinarello CA, Kaplanski G. Cauchois R, et al. Proc Natl Acad Sci U S A. 2020 Aug 11;117(32):18951-18953. doi: 10.1073/pnas.2009017117. Epub 2020 Jul 22. Proc Natl Acad Sci U S A. 2020. PMID: 32699149 Free PMC article.
Because interleukin-1 (IL-1) blocks the production of IL-6 and other proinflammatory cytokines, we treated COVID-19 patients early in the disease with the IL-1 receptor antagonist, anakinra. We retrospectively compared 22 patients from three different centers in France wit …
Because interleukin-1 (IL-1) blocks the production of IL-6 and other proinflammatory cytokines, we treated COVID-19 patients early in the di …
1-Year Outcomes of Angina Management Guided by Invasive Coronary Function Testing (CorMicA).
Ford TJ, Stanley B, Sidik N, Good R, Rocchiccioli P, McEntegart M, Watkins S, Eteiba H, Shaukat A, Lindsay M, Robertson K, Hood S, McGeoch R, McDade R, Yii E, McCartney P, Corcoran D, Collison D, Rush C, Sattar N, McConnachie A, Touyz RM, Oldroyd KG, Berry C. Ford TJ, et al. JACC Cardiovasc Interv. 2020 Jan 13;13(1):33-45. doi: 10.1016/j.jcin.2019.11.001. Epub 2019 Nov 11. JACC Cardiovasc Interv. 2020. PMID: 31709984 Free PMC article. Clinical Trial.
Pre-specified endpoints included 1-year patient-reported outcome measures (Seattle Angina Questionnaire, quality of life [EQ-5D]) and major adverse cardiac events (all-cause mortality, myocardial infarction, unstable angina hospitalization or revascularization, hear …
Pre-specified endpoints included 1-year patient-reported outcome measures (Seattle Angina Questionnaire, quality of life [EQ-5D]) and …
Subacromial decompression surgery for rotator cuff disease.
Karjalainen TV, Jain NB, Page CM, Lähdeoja TA, Johnston RV, Salamh P, Kavaja L, Ardern CL, Agarwal A, Vandvik PO, Buchbinder R. Karjalainen TV, et al. Cochrane Database Syst Rev. 2019 Jan 17;1(1):CD005619. doi: 10.1002/14651858.CD005619.pub3. Cochrane Database Syst Rev. 2019. PMID: 30707445 Free PMC article.
Major outcomes were mean pain scores, shoulder function, quality of life, participant global assessment of success, adverse events and serious adverse events. The primary endpoint for this review was one year. ...Although precise estimates are unknown, the risk of s …
Major outcomes were mean pain scores, shoulder function, quality of life, participant global assessment of success, adverse events an …
Complications and outcome after rib fracture fixation: A systematic review.
Peek J, Beks RB, Hietbrink F, Heng M, De Jong MB, Beeres FJP, Leenen LPH, Groenwold RHH, Houwert RM. Peek J, et al. J Trauma Acute Care Surg. 2020 Aug;89(2):411-418. doi: 10.1097/TA.0000000000002716. J Trauma Acute Care Surg. 2020. PMID: 32282759
The most frequently used questionnaire to assess patient quality of life was the EuroQol-5D (EQ-5D) (n = 4). Four studies reporting on the EQ-5D had a weighted mean EQ-5D index of 0.80 indicating good quality of life after rib fracture fixation. ...
The most frequently used questionnaire to assess patient quality of life was the EuroQol-5D (EQ-5D) (n = 4). Four studies repo …
Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057.
Reck M, Brahmer J, Bennett B, Taylor F, Penrod JR, DeRosa M, Dastani H, Spigel DR, Gralla RJ. Reck M, et al. Eur J Cancer. 2018 Oct;102:23-30. doi: 10.1016/j.ejca.2018.05.005. Epub 2018 Aug 10. Eur J Cancer. 2018. PMID: 30103096 Clinical Trial.
LCSS 3-item global index (3-IGI), EQ-5D utility index and EQ-5D visual analogue scale (VAS) scores were also determined. Mixed-effects model repeated measures (MMRM) and time to first deterioration analyses assessed longitudinal changes. ...
LCSS 3-item global index (3-IGI), EQ-5D utility index and EQ-5D visual analogue scale (VAS) scores were also determined. Mixed …
Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF.
McEwan P, Darlington O, McMurray JJV, Jhund PS, Docherty KF, Böhm M, Petrie MC, Bergenheim K, Qin L. McEwan P, et al. Eur J Heart Fail. 2020 Nov;22(11):2147-2156. doi: 10.1002/ejhf.1978. Epub 2020 Sep 15. Eur J Heart Fail. 2020. PMID: 32749733 Free PMC article.
Direct healthcare costs (2019 British pounds/Euro) and patient-reported outcomes (EQ-5D) were sourced from the existing literature and the Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure trial (DAPA-HF), respectively; the median duration of follow- …
Direct healthcare costs (2019 British pounds/Euro) and patient-reported outcomes (EQ-5D) were sourced from the existing literature an …
417 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page